More people died following Pfizer’s COVID-19 vaccine vs.

New Post Public Reply Private Reply Replies (0) Message Board
Rusty
459
More people died following Pfizer’s COVID-19 vaccine vs. a placebo during clinical trial

Nobody can truthfully claim that Pfizer’s Wuhan coronavirus (COVID-19) vaccine has been proven by a clinical trial to save lives. Still, people are being pressured to receive the vaccine under threat of court-martial, loss of employment, denial of medical treatment and exclusion from normal life.

On Nov. 8, the Food and Drug Administration published a report updating the clinical trial results of Pfizer’s mRNA-based COVID-19 vaccine. The trial included around 44,000 people over the age of 16, equally divided into two groups. One group received the vaccine and the other a placebo.

Page 23 of the report showed that over the course of the trial, there were a total of 38 deaths among participants: 21 in the vaccinated group and 17 in the placebo group. Because the number of deaths in the vaccinated group was not significantly less than the placebo group (but is, in fact, more than the placebo group), the vaccine failed to prove itself by the standard of all-cause mortality.

All-cause mortality is the number of deaths due to any cause in both the control and treated groups of a clinical trial. This is the most reliable clinical endpoint for the evaluation of a medical treatment that is supposed to reduce mortality because it is objective and properly accounts for unanticipated effects, which may offset the anticipated benefits of a treatment.

The National Academy of Sciences published a volume that explained the evaluative advantage of all-cause mortality with many lessons from the annals of medical history. A contributor to the volume, renowned anesthetist John P. Bunker, said: “When dealing with mortality as an endpoint of treatment, all-cause mortality is ignored at the peril of the investigators and the public.”

The burden of proving statistical significance is on the vaccine, not the placebo. The primary hypothesis of the clinical trial was that the vaccine would save lives, and for the hypothesis to be upheld, the death rate in the vaccinated group had to be significantly less than that of the placebo group – which did not happen in this case.

There is currently no scientific basis for retaining the hypothesis that the administration of the Pfizer COVID-19 vaccine could save lives.

However, there are reasons besides vaccination why the COVID death rate may be higher in one society than another, including population-age distributions, vaccinations and even access to therapeutics.

The most obvious problem, however, is the reinforcing bias of the clinician, who knows whether or not the patient has been COVID-vaccinated.

Among multiple comorbidities, the clinician might be more likely to attribute the death to COVID if he or she knows that the patient is not vaccinated.

If this happens, then the clinicians in populations with a higher vaccination rate would be less likely to attribute the deaths to COVID than the clinicians in populations with lower vaccination rates.

None of the trials were designed to detect a reduction in any serious outcomes such as hospitalizations and deaths. While the vaccines are hailed to be the solution to the pandemic, clinical trials could not and did not prove that they can save lives. None of the vaccines studied were supported by concrete evidence to be able to interrupt the transmission of the virus.

Part of the reason for the lack of convincing results may be the numbers, because most people with symptomatic COVID-19 infections only experience mild symptoms, even for trials involving 30,000 or more patients.

“Hospitalizations and deaths from covid-19 are simply too uncommon in the population being studied for an effective vaccine to demonstrate statistically significant differences in a trial of 30,000 people.

The same is true regarding whether it can save lives or prevent transmission.

The trials are not designed to find out,” said Peter Doshi, associate editor at the global healthcare knowledge publication, BMJ.


https://sciencefraud.news/2021-12-10-pfizer-v...ives.html#
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LITEON's Q3 Surge: Record Profits, AI Focus Amplified

Updated Category News Views 79

LITEON Smashes Q3 Records, Financials Speak Volumes You don't find numbers like these under every rock. LITEON Technology is rolling in it after clinching third quarter revenues of NT$57.4 billion, marking a significant 9% growth compared to the previous quarter and a whopping 28% surge year-over-year. That's the kind of financial football that gets investors holding onto...

Continue Reading
Military Medical Minds to Converge at MTEC Event in 2027

Updated Category News Views 72

Ever wonder where the cutting edge of military medicine takes shape? On February 16-17, 2027, Washington, DC becomes the epicenter for just that, as the Medical Technology Enterprise Consortium (MTEC) rolls out its 11th Annual Membership Meeting. A gathering of who's who in the world of military medical innovation, this event is like a high-stakes cocktail of science,...

Continue Reading
Polypropylene Takes a Quantum Leap with Dyeability Boost

Updated Category News Views 53

Revolutionizing Polypropylene’s Dyeability Problem There's a new kid on the block in the textile world, and it's turning heads for good reason. Picture this: polypropylene, which typically struggled with dyeability, now boasting a PET-like finish, thanks to a groundbreaking collaboration between Newlight Technologies and Prime Polymer. They've taken polypropylene and...

Continue Reading
D-Wave Faces Securities Fraud Class Action: Details Inside

Updated Category News Views 41

D-Wave Quantum Inc. in Hot Water Well folks, looks like D-Wave Quantum Inc. (NASDAQ: QBTS) is knee-deep in a securities fraud class action lawsuit. This ain't just another day in the quantum computing trenches. We've got Kessler Topaz Meltzer & Check, LLP, a big player in securities litigation, rallying the troops here—a clear sign that this case is packing some hefty...

Continue Reading
Fluence Energy Faces Class Action with 34.63% Stock Drop

Updated Category News Views 56

Rough Times for Fluence Energy Shareholders Fluence Energy, Inc. (NASDAQ:FLNC) has been treading choppy waters with a stock plunge of 34.63%, leaving investors gasping for air. This isn't your typical market jitters—it's tied up with a securities fraud class action, which seems to have taken the wind right out of their sails. In the twisted world of energy stocks, any...

Continue Reading
Navigating New Home Builds: Tucson’s Precise Timelines

Updated Category News Views 69

Building a Home in Tucson: Timing is Everything Ask anyone who's ever dreamed of their own custom-built home—patience isn't just a virtue, it's a necessity. In Tucson, Arizona, where the landscape is as captivating as it is challenging, Home Remodeling Expert Robin Hartman breaks down exactly what homeowners should expect when embarking on a home build. Hartman, through...

Continue Reading
Gutiérrez Honored with Enrique V. Iglesias Award

Updated Category News Views 5

Gutiérrez Recognized for Civic and Business Impact Alright, folks, here's a scenario to chew on: Dionisio Gutiérrez, a name that's likely resonated in business and civic corridors for a while, is about to add another feather to his cap. This November 4, Gutiérrez will bask in the limelight as King Felipe VI of Spain hands him the 11th Enrique V. Iglesias Award. It's...

Continue Reading
Maya Mobile Wins Best Global Roaming Services 2026

Updated Category News Views 40

Travelers Speak: Maya Tops Global Roaming It's not every day that you see the travel community collectively high-five a company, but that's precisely what happened with Maya Mobile. These folks just snagged the Best Global Roaming Services title at the TripZilla Excellence Awards 2026, and it's not just fluff—it's voted by travelers. This ain't your typical pat on the...

Continue Reading
Vanity Fair Lingerie Reveals New Smoothing Bra

Updated Category News Views 66

A Bra Revolution or Just Another Launch? I'll admit it, lingerie isn't the usual breakfast discussion for me, but Vanity Fair Lingerie's move with their new Flawlessly Smooth™ Bra piqued my interest. Announced in Bowling Green, Kentucky, on November 2, 2026, and set against the lavish backdrop of an upcoming New York City event cohosted by Cosmopolitan, it's less about...

Continue Reading
Good Springs Earns Spot on Inc.'s 2026 Founder List

Updated Category News Views 31

There's a badge of honor in the investment world that's not about the dollars and cents pouring in—it's about having founders trust you to take care of their business babies. Good Springs Capital just snagged one by being named to Inc.'s 2026 Founder-Friendly Investors list. Now, if you're thinking this is just some fancy accolade, let's chew over the real nuggets here....

Continue Reading

Top 5 Most Recently Viewed Articles

Porton Advanced Gains Class C License for CGT Scale-Up

Updated Category News Views 46

Milestone for Porton Advanced: Class C License Secured Look who's leveling up in the CGT game! No small feat here—Porton Advanced, having just snagged a Drug Manufacturing License Class C from the NMPA, can now waltz its way from development into commercial manufacturing. This makes the company an even bigger player in the Contract Development and Manufacturing...

Continue Reading
Benson Boone Celebrated with BMI Champion Award at 2025 Event

Updated Category News Views 455

Benson Boone Honored at the BMI Pop Awards Benson Boone, a GRAMMY-nominated singer-songwriter, is set to receive the esteemed BMI Champion Award during the upcoming BMI Pop Awards. This significant recognition highlights not only Boone's impact on the music industry but also his dedication to artistry. A Night of Celebration The BMI Pop Awards will feature a gala event...

Continue Reading
ECARX Reports Impressive Growth in First Quarter Financials

Updated Category News Views 244

ECARX Holdings Inc. Reports Impressive First Quarter Growth ECARX Holdings Inc. (Nasdaq: ECX), a key player in the global mobility tech sector, has unveiled its unaudited financial results for the first quarter of 2025. The company continues to build on the momentum achieved throughout the previous year, demonstrating a robust performance amidst dynamic market conditions....

Continue Reading
Chadwick Westlake to Present at Scotiabank Financials Summit

Updated Category News Views 154

Chadwick Westlake to Present at Scotiabank's Financial Services Summit Chadwick Westlake, the esteemed President and CEO of EQB Inc., which encompasses Equitable Bank, Canada's premier Challenger Bank™, is set to speak at the Scotiabank's 26th Annual Financial Services Summit. This event is scheduled for September 3 and is bound to attract significant interest from...

Continue Reading
Groundbreaking SPECT Imaging Study Enhances Prostate Cancer Care

Updated Category News Views 173

Innovative Approach to Prostate Cancer Imaging Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX) and the Oncidium foundation have recently made a significant advancement in prostate cancer imaging with the publication of results from their NOBLE Registry study. This collaborative effort aims to enhance equity in access to state-of-the-art prostate cancer imaging...

Continue Reading